Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month for proteinuria reduction.

Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at the IgAN patient journey amid a rapidly evolving ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...

A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the third time. In September, J&J, via a subsidiary called Red River Talc, filed ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...

Sarepta and Roche will share the monitors' findings with EMA to resolve a temporary hold. Elsewhere, Allakos agreed to a buyout and high-dose Ocrevus missed a study goal.

Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...

Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...